DD261094A5 - Verwendung der verbindung 1-beta-d-ribofuranosyl-1,2,4,-triazol-3-carbonsaeureamid zur herstellung einer pharmazeutischen zusammensetzung - Google Patents

Verwendung der verbindung 1-beta-d-ribofuranosyl-1,2,4,-triazol-3-carbonsaeureamid zur herstellung einer pharmazeutischen zusammensetzung Download PDF

Info

Publication number: DD261094A5
Authority: DD; German Democratic Republic
Prior art keywords: compound; item; use according; patients; virus
Prior art date: 1984-10-29

Application number

DD85281565A

Other languages

German (de)

English (en)

Inventor

Roberts A Smith

Humberto Fernandez

Original Assignee

Kkk

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-10-29

Filing date

1985-10-09

Publication date

1988-10-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24673430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD261094(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1985-10-09 Application filed by Kkk filed Critical Kkk

1988-10-19 Publication of DD261094A5 publication Critical patent/DD261094A5/de

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 22
239000008194 pharmaceutical composition Substances 0.000 title claims description 3
238000004519 manufacturing process Methods 0.000 title claims 2
241000700605 Viruses Species 0.000 claims abstract description 43
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 35
201000010099 disease Diseases 0.000 claims abstract description 34
230000003612 virological effect Effects 0.000 claims abstract description 21
241000725643 Respiratory syncytial virus Species 0.000 claims abstract description 12
241000712891 Arenavirus Species 0.000 claims abstract description 9
241001430294 unidentified retrovirus Species 0.000 claims abstract description 5
239000003814 drug Substances 0.000 claims description 12
229940079593 drug Drugs 0.000 claims description 8
208000002491 severe combined immunodeficiency Diseases 0.000 claims description 8
241000282412 Homo Species 0.000 claims description 7
239000000443 aerosol Substances 0.000 claims description 7
208000011580 syndromic disease Diseases 0.000 claims description 7
206010061598 Immunodeficiency Diseases 0.000 claims description 4
210000002345 respiratory system Anatomy 0.000 claims description 4
208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
208000019693 Lung disease Diseases 0.000 claims description 3
230000007813 immunodeficiency Effects 0.000 claims description 3
238000002347 injection Methods 0.000 claims description 3
239000007924 injection Substances 0.000 claims description 3
208000002330 Congenital Heart Defects Diseases 0.000 claims description 2
239000000203 mixture Substances 0.000 claims 6
206010028980 Neoplasm Diseases 0.000 abstract description 8
241000713112 Orthobunyavirus Species 0.000 abstract description 2
239000002831 pharmacologic agent Substances 0.000 abstract 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 33
229960000329 ribavirin Drugs 0.000 description 32
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 31
208000015181 infectious disease Diseases 0.000 description 12
208000024891 symptom Diseases 0.000 description 12
208000032982 Hemorrhagic Fever with Renal Syndrome Diseases 0.000 description 11
208000016028 Korean hemorrhagic fever Diseases 0.000 description 11
206010023927 Lassa fever Diseases 0.000 description 9
241001465754 Metazoa Species 0.000 description 7
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 7
208000030507 AIDS Diseases 0.000 description 6
206010061192 Haemorrhagic fever Diseases 0.000 description 6
239000003443 antiviral agent Substances 0.000 description 6
241001493065 dsRNA viruses Species 0.000 description 6
239000000902 placebo Substances 0.000 description 6
229940068196 placebo Drugs 0.000 description 6
206010010099 Combined immunodeficiency Diseases 0.000 description 5
206010035664 Pneumonia Diseases 0.000 description 5
230000029142 excretion Effects 0.000 description 5
230000000241 respiratory effect Effects 0.000 description 5
230000009385 viral infection Effects 0.000 description 5
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
238000000034 method Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
206010006448 Bronchiolitis Diseases 0.000 description 3
206010011224 Cough Diseases 0.000 description 3
241000150562 Hantaan orthohantavirus Species 0.000 description 3
102100034343 Integrase Human genes 0.000 description 3
206010035742 Pneumonitis Diseases 0.000 description 3
206010037660 Pyrexia Diseases 0.000 description 3
208000037656 Respiratory Sounds Diseases 0.000 description 3
206010044314 Tracheobronchitis Diseases 0.000 description 3
206010058874 Viraemia Diseases 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
229940127089 cytotoxic agent Drugs 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
206010009192 Circulatory collapse Diseases 0.000 description 2
206010011703 Cyanosis Diseases 0.000 description 2
208000004232 Enteritis Diseases 0.000 description 2
241000712003 Human respirovirus 3 Species 0.000 description 2
208000007766 Kaposi sarcoma Diseases 0.000 description 2
208000009525 Myocarditis Diseases 0.000 description 2
201000007100 Pharyngitis Diseases 0.000 description 2
206010047924 Wheezing Diseases 0.000 description 2
229960004150 aciclovir Drugs 0.000 description 2
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
238000010171 animal model Methods 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
201000010549 croup Diseases 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000002008 hemorrhagic effect Effects 0.000 description 2
230000004199 lung function Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000002663 nebulization Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
206010037844 rash Diseases 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
JGRLGSOSBSHJIR-FNKGTGPASA-N ribavirin carboxylic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=C(C(O)=O)N=C1 JGRLGSOSBSHJIR-FNKGTGPASA-N 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
206010040560 shock Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000000779 thoracic wall Anatomy 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
ZEWJFUNFEABPGL-UHFFFAOYSA-N 1,2,4-triazole-3-carboxamide Chemical compound NC(=O)C=1N=CNN=1 ZEWJFUNFEABPGL-UHFFFAOYSA-N 0.000 description 1
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
208000003829 American Hemorrhagic Fever Diseases 0.000 description 1
241000700179 Apodemus Species 0.000 description 1
241001529533 Apodemus agrarius Species 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
206010004053 Bacterial toxaemia Diseases 0.000 description 1
208000034200 Bolivian hemorrhagic fever Diseases 0.000 description 1
201000004813 Bronchopneumonia Diseases 0.000 description 1
206010008583 Chloroma Diseases 0.000 description 1
206010011416 Croup infectious Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
208000015220 Febrile disease Diseases 0.000 description 1
208000021727 Hantavirus hemorrhagic fever with renal syndrome Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000001688 Herpes Genitalis Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241000711941 Murine orthopneumovirus Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
206010042241 Stridor Diseases 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
208000013222 Toxemia Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
229960004484 carbachol Drugs 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000010460 detection of virus Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
239000006260 foam Substances 0.000 description 1
201000004946 genital herpes Diseases 0.000 description 1
208000017750 granulocytic sarcoma Diseases 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
201000005987 myeloid sarcoma Diseases 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000010309 neoplastic transformation Effects 0.000 description 1
208000020470 nervous system symptom Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
210000005267 prostate cell Anatomy 0.000 description 1
238000009613 pulmonary function test Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000036387 respiratory rate Effects 0.000 description 1
208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 1
229940065826 ribavirin 20 mg/ml Drugs 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Virology (AREA)
Oncology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

DD85281565A 1984-10-29 1985-10-09 Verwendung der verbindung 1-beta-d-ribofuranosyl-1,2,4,-triazol-3-carbonsaeureamid zur herstellung einer pharmazeutischen zusammensetzung DD261094A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US66625284A	1984-10-29	1984-10-29

Publications (1)

Publication Number	Publication Date
DD261094A5 true DD261094A5 (de)	1988-10-19

Family

ID=24673430

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD85281565A DD261094A5 (de)	1984-10-29	1985-10-09	Verwendung der verbindung 1-beta-d-ribofuranosyl-1,2,4,-triazol-3-carbonsaeureamid zur herstellung einer pharmazeutischen zusammensetzung

Country Status (18)

Country	Link
EP (3)	EP0383361A3 (fr)
JP (1)	JPH0713019B2 (fr)
KR (1)	KR860003018A (fr)
AT (1)	ATE204173T1 (fr)
AU (1)	AU584333B2 (fr)
BE (1)	BE902199A (fr)
CA (1)	CA1261265A (fr)
DD (1)	DD261094A5 (fr)
DE (3)	DE3588232T2 (fr)
ES (1)	ES8704962A1 (fr)
FR (1)	FR2572286B1 (fr)
GB (1)	GB2166050B (fr)
LU (1)	LU85854A1 (fr)
NL (1)	NL300083I1 (fr)
NZ (1)	NZ212510A (fr)
PH (1)	PH22534A (fr)
PT (1)	PT81387B (fr)
ZA (1)	ZA858237B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE126696T1 (de) *	1985-12-23	1995-09-15	Hutchinson Fred Cancer Res	Regulierung der retroviralen replikation, infektion und pathogenese.
JP2792246B2 (ja) *	1991-01-31	1998-09-03	信越半導体株式会社	単結晶棒クランプ位置決め治具及びこれを用いた単結晶棒クランプ位置決め方法
PL364699A1 (en) *	1999-01-29	2004-12-13	Icn Pharmaceuticals, Inc.	Modulation of immune response by ribavirin
US6720000B2 (en)	2001-03-19	2004-04-13	Three Rivers Pharmaceutical, Llc	Process for producing wet ribavirin pellets
US7132453B2 (en) *	2002-03-15	2006-11-07	Vanderbilt University	Method of using prostacyclin to treat respiratory syncytial virus infections
US7538094B2 (en)	2002-09-19	2009-05-26	Three Rivers Pharmacueticals, Llc	Composition containing ribavirin and use thereof
US20170128482A1 (en)	2014-06-23	2017-05-11	Sanovel Ilac Sanayi Ve Ticaret A.S.	Modified release pharmaceutical compositions of sofosbuvir and ribavirin
US20170151272A1 (en)	2014-06-23	2017-06-01	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A novel pharmaceutical composition of sofosbuvir and ribavirin
EA201692507A1 (ru)	2014-06-23	2017-04-28	Сановель Илач Санайи Ве Тиджарет А.Ш.	Фармацевтические комбинации софосбувира и рибавирина
JP2018076280A (ja) *	2016-10-28	2018-05-17	国立大学法人大分大学	ジカウイルス感染症治療用医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3798209A (en) *	1971-06-01	1974-03-19	Icn Pharmaceuticals	1,2,4-triazole nucleosides
US3927216A (en) *	1971-06-01	1975-12-16	Icn Pharmaceuticals	1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US4211771A (en) *	1971-06-01	1980-07-08	Robins Ronald K	Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
AR205339A1 (es) *	1973-03-12	1976-04-30	Icn Pharmaceuticals	Sintesis de 1,2,4-triazolo-3-carboxamidas utiles como agentes antivirales
WO1983003383A1 (fr) *	1982-03-29	1983-10-13	Liposome Co Inc	Vesicules plurilamellaires stables

1985
- 1985-04-15 BE BE0/214849A patent/BE902199A/fr not_active IP Right Cessation
- 1985-04-16 GB GB8509689A patent/GB2166050B/en not_active Expired
- 1985-04-16 DE DE3588232T patent/DE3588232T2/de not_active Expired - Lifetime
- 1985-04-16 DE DE198585302644T patent/DE181050T1/de active Pending
- 1985-04-16 AT AT94118300T patent/ATE204173T1/de active
- 1985-04-16 EP EP19900105678 patent/EP0383361A3/fr not_active Withdrawn
- 1985-04-16 EP EP85302644A patent/EP0181050A3/fr not_active Withdrawn
- 1985-04-16 EP EP94118300A patent/EP0643970B1/fr not_active Revoked
- 1985-04-16 DE DE2002199005 patent/DE10299005I2/de active Active
- 1985-04-17 LU LU85854A patent/LU85854A1/fr unknown
- 1985-04-30 AU AU41807/85A patent/AU584333B2/en not_active Expired
- 1985-05-07 CA CA000480878A patent/CA1261265A/fr not_active Expired
- 1985-05-16 PH PH32282A patent/PH22534A/en unknown
- 1985-05-30 FR FR858508143A patent/FR2572286B1/fr not_active Expired - Fee Related
- 1985-05-30 KR KR1019850003752A patent/KR860003018A/ko not_active Ceased
- 1985-06-05 JP JP60122351A patent/JPH0713019B2/ja not_active Expired - Fee Related
- 1985-06-21 NZ NZ212510A patent/NZ212510A/xx unknown
- 1985-10-09 DD DD85281565A patent/DD261094A5/de active Search and Examination
- 1985-10-28 ZA ZA858237A patent/ZA858237B/xx unknown
- 1985-10-28 PT PT81387A patent/PT81387B/pt active IP Right Revival
- 1985-10-29 ES ES548303A patent/ES8704962A1/es not_active Expired
2002
- 2002-02-14 NL NL300083C patent/NL300083I1/nl unknown

Also Published As

Publication number	Publication date
ES548303A0 (es)	1987-04-16
JPH0713019B2 (ja)	1995-02-15
ZA858237B (en)	1988-02-24
DE181050T1 (de)	1986-12-18
CA1261265A (fr)	1989-09-26
HK1010985A1 (en)	1999-07-02
DE10299005I1 (de)	2002-05-08
LU85854A1 (fr)	1985-12-16
NL300083I1 (nl)	2002-05-01
DE3588232D1 (de)	2001-09-20
AU584333B2 (en)	1989-05-25
EP0643970B1 (fr)	2001-08-16
EP0181050A3 (fr)	1987-10-21
PT81387B (pt)	1987-11-11
DE10299005I2 (de)	2004-07-01
PT81387A (en)	1985-11-01
GB2166050A (en)	1986-04-30
FR2572286B1 (fr)	1990-03-23
EP0181050A2 (fr)	1986-05-14
GB8509689D0 (en)	1985-05-22
AU4180785A (en)	1986-05-08
BE902199A (fr)	1985-07-31
PH22534A (en)	1988-10-17
JPS61109723A (ja)	1986-05-28
GB2166050B (en)	1989-08-16
EP0643970A3 (fr)	1997-07-09
EP0643970A2 (fr)	1995-03-22
NZ212510A (en)	1989-04-26
DE3588232T2 (de)	2002-06-13
FR2572286A1 (fr)	1986-05-02
EP0383361A3 (fr)	1993-06-16
KR860003018A (ko)	1986-05-19
ATE204173T1 (de)	2001-09-15
ES8704962A1 (es)	1987-04-16
EP0383361A2 (fr)	1990-08-22

Legal Events

Date	Code	Title	Description
1997-05-07	RPV	Change in the person, the name or the address of the representative (searches according to art. 11 and 12 extension act)
1997-05-22	EP	Request for examination under paragraph 12(1) filed
2002-11-21	RPI	Change in the person, name or address of the patentee (searches according to art. 11 and 12 extension act)
2004-04-28	ASS	Change of applicant or owner	Owner name: RIBAPHARM, INC., COSTA MESA, CA 9262 Effective date: 20020913
2004-04-28	IF04	In force in the year 2004	Expiry date: 20051010

Publication	Publication Date	Title
DE69430440T2 (de)	2002-11-14	Zusammensetzungen zur inhibition von retroviraler verbreitung, die 2',3'-dideoxy-inosin und hydroxyharnstoff enthalten
DE69632034T2 (de)	2004-10-14	Pharmazeutische zubereitung zur topischen applikation enthaltend acyclovir und hydrokortison
DE69306545T2 (de)	1997-04-03	Tucaresol als Mittel zur Immunopotentierung
EP2249866B1 (fr)	2012-08-15	Utilisation d'un sel d'acide acétylsalicylique pour le traitement d'infections virales
DE2728685A1 (de)	1978-01-12	Arzneimittel
DE3855323T2 (de)	1996-10-10	Galenische 2-beta-Mimetik-Formen für die per- und sublinguale Verabreichung
DE60036862T2 (de)	2008-08-14	Synergistische hemmung von viralreplikation durch langkettigen kohlenwasserstoffe und nucleosid-analoge
DD261094A5 (de)	1988-10-19	Verwendung der verbindung 1-beta-d-ribofuranosyl-1,2,4,-triazol-3-carbonsaeureamid zur herstellung einer pharmazeutischen zusammensetzung
DE3873207T2 (de)	1993-01-07	Antivirale therapie gegen hepatitis b mit 2',3'-didesoxynucleosiden.
JP2724711B2 (ja)	1998-03-09	医薬品生成物
EP0374096B1 (fr)	1992-12-02	Thérapie combinée utilisant le 2',5'-didéoxypurine nucléoside et inhibiteur de purine nucléoside-phosphorylase et ses compositions
DE69830154T2 (de)	2005-10-13	Pharmazeutische zusammensetzungen
DE69527713T2 (de)	2003-04-10	Verbindunngen und zusammensetzungen zur verabreichung via inhalation und insufflierung
DE69019404T2 (de)	1995-10-12	Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen.
DE60118592T2 (de)	2007-05-16	Verbindungen aus phyllanthus zur prävention und/oder behandlung von erkrankungen im zusammenhang mit einem retrovirus
DE69902879T2 (de)	2003-04-30	Pflanzliches antivirales mittel
DE3881864T2 (de)	1993-09-30	Antivirale zusammensetzungen mit aromatischen polycyclischen dionen sowie methode zur behandlung retroviraler infektionen.
DE69328102T2 (de)	2000-11-09	Verwendung von gift aus hautflüglern (hymenopteren) zur herstellung eines medikamentes zur behandlung von infektionen durch dna-viren
DE2325070A1 (de)	1973-11-29	Pharmazeutische zubereitungen zur prophylaxe und zur behandlung von kapillarvenoesen erkrankungen
DE3440621A1 (de)	1985-05-23	Pharmazeutische zusammensetzung zur bekaempfung von vireninfektionen und deren verwendung
DE3141970C2 (fr)	1987-09-24
DE69523776T2 (de)	2002-08-01	Verwendung von aminopurinen antiviralen mitteln zur behandlung und prophylaxe der latenten herpes-virus infektionen
DE2305553A1 (de)	1973-08-09	Arzneimittel zur behandlung von virusinfektionen
EP2818167A1 (fr)	2014-12-31	Composition pharmaceutique antivirale active
CH675538A5 (fr)	1990-10-15